{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 42,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/19",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.49,
        "w": 0.357,
        "x": 0.59,
        "y": 0.19
      },
      "kind": "chart",
      "text": "APX3330 prevents VEGF overproduction in ARPE-19 cells; VEGF Concentrations (% of Control); ARPE-19 cell line; oxLDL; APX3330; 150µg/mL; 30µM; p<0.05",
      "attrs": {},
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d60a137-9825-49b3-9721-807a574ea44a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.54,
        "x": 0.045,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Normal Conditions: Physiological level of VEGF activity; Abnormal Conditions (e.g., hypoxic): Increased level of VEGF activity; Biologic anti-VEGF agents inactivate VEGF directly and reduce VEGF levels below normal levels; Biologic Anti-VEGF Treatment; APX3330 Anti-Ref-1 Treatment; Inhibition of Ref-1 by APX3330 returns VEGF levels to normal levels",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07a80289-55b0-4de5-a5cd-9ab179470831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.08,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39f44613-d86d-4219-8898-f8ccfa352ff3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.929,
        "x": 0.04,
        "y": 0.81
      },
      "kind": "list",
      "text": "The safety profile of APX3330 to date has not shown any of the adverse effects that has been seen with systemic administration of anti-VEGF biologics such as cardiovascular pathology, hypertension, arteriothrombotic events, or renal dysfunction",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9471b928-1f2d-4f53-b76f-477fdcfad14c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.929,
        "x": 0.04,
        "y": 0.733
      },
      "kind": "list",
      "text": "VEGF is a growth factor that is necessary for normal function of multiple cell types including vascular endothelium and neurons → By returning VEGF levels to normal, APX3330 can reduce neovascularization, vascular leakage and the inflammatory response without adverse systemic effects",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d93505a9-dbf7-4ca9-afdd-e11beeef0899",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.016,
        "x": 0.953,
        "y": 0.953
      },
      "kind": "other",
      "text": "19",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6260243f-0a03-4bf5-a86b-5b4566e138ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.24,
        "x": 0.128,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Kamba 2007; Girardi 2010; Li 2014 APX3330 Investigator Brochure",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9123bba0-caa8-429b-8c3f-43cc80397ac1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.766,
        "x": 0.048,
        "y": 0.083
      },
      "kind": "title",
      "text": "APX3330 Restores Normal Levels Unlike Biologic Anti-VEGFs that Reduce VEGF Below Normal",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc5b53af-7113-4fe0-81ba-298076a7e450",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.609,
        "x": 0.048,
        "y": 0.049
      },
      "kind": "title",
      "text": "APX3330 VEGF Effects in Normal Cells",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cec3d6e6-4901-48a7-ac81-4b990bd7ab99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 17,
      "beatId": "65814d93-901f-41c1-8ee8-b0d5c8ea9369",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 17-28 provide clinical trial results and data for APX3330",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}